Faculty, Staff and Student Publications
Publication Date
10-1-2024
Journal
Lancet Oncology
DOI
10.1016/S1470-2045(24)00264-X
PMID
39362260
PMCID
PMC11778933
PubMedCentral® Posted Date
1-29-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
NRG Oncology's Developmental Therapeutics and Radiation Therapy Subcommittee assembled an interdisciplinary group of investigators to address barriers to successful early phase clinical trials of novel combination therapies involving radiation. This Policy Review elucidates some of the many challenges associated with study design for early phase trials combining radiotherapy with novel systemic agents, which are distinct from drug-drug combination development and are often overlooked. We also advocate for potential solutions that could mitigate or eliminate some of these barriers, providing examples of specific clinical trial designs that could help facilitate efficient and effective evaluation of novel drug-radiotherapy combinations.
Keywords
Animals, Antineoplastic Agents, Biomarkers, Tumor, Chemoradiotherapy, Clinical Trials as Topic, Drug Discovery, Drug Interactions, Neoplasm Staging, Neoplasms, Societies, Medical, Humans
Published Open-Access
yes
Recommended Citation
Zumsteg, Zachary S; Sheth, Siddharth; Jabbour, Salma K; et al., "Challenges and Opportunities for Early Phase Clinical Trials of Novel Drug-Radiotherapy Combinations: Recommendations From Nrg Oncology, the American Society for Radiation Oncology (Astro), The American College of Radiology (Acr), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (Acro)" (2024). Faculty, Staff and Student Publications. 3573.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/3573
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons